Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)

Summary

This is a phase I study designed to assess the maximum tolerated dose (MTD) of pyrimethamine and provide the recommended Phase 2 dose (RP2D) for the treatment of intermediate/high-risk MDS that is refractory to or relapsed after treatment with azanucleosides.

Timeline

Start

2019-09-11

Primary completion

2021-06-29

Completion

2021-06-29

Drugs

Indications